Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 6026 - 6050 of 6770 in total

N-(2-Aminoethyl)-5-Chloroisoquinoline-8-Sulfonamide

Experimental

1-[(2-AMINO-4-CHLORO-5-METHYLPHENYL)SULFONYL]-L-PROLINE

Experimental

(2S)-1-(2,5-dimethylphenoxy)-3-morpholin-4-ylpropan-2-ol

Experimental

B7-H3-specific chimeric antigen receptor T cells

Investigational

Vonlerolizumab

Vonlerolizumab is under investigation in clinical trial NCT03029832 (A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Therapy).
Investigational

Trabedersen

Investigational

Pegpleranib

Investigational

Clazosentan

Investigational

Enviomycin

Cyclic basic peptide related to viomycin. It is isolated from an induced mutant of Streptomyces griseoverticillatus var. tuberacticus and acts as an antitubercular agent with less ototoxicity than tuberactinomycin.
Experimental

Faldaprevir

Faldaprevir has been investigated for the treatment of Chronic Hepatitis C.
Investigational

Varespladib

Varespladib has been investigated for the treatment and prevention of Sickle Cell Disease, Vaso-occlusive Crisis, and Acute Coronary Syndrome.
Investigational

Englitazone

Englitazone is a hypoglycemic agent.
Experimental

p-Toluenesulfonic acid

Experimental

Tuspetinib

Tuspetinib (HM-43239) is under investigation in clinical trial NCT03850574 (Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients With Relapsed or Refractory Acute Myeloid Leukemia).
Investigational

Danicamtiv

Danicamtiv is under investigation in clinical trial NCT04572893 (Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other Causalities).
Investigational

Tobevibart

Tobevibart is under investigation in clinical trial NCT05612581 (A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection).
Investigational

1,2-Di-N-Pentanoyl-Sn-Glycero-3-Dithiophosphocholine

Experimental

N-(3-Phenyl-2-Sulfanylpropanoyl)Phenylalanylalanine

Experimental

1,2,3,4-Tetrahydro-Isoquinoline-7-Sulfonic Acid Amide

Experimental

1-N-(4-SULFAMOYLPHENYL-ETHYL)-2,4,6-TRIMETHYLPYRIDINIUM

Experimental

2,5-O,O-BIS-{4',4''-AMIDINOPHENYL}-1,4:3,6-DIANHYDRO-D-SORBITOL

Experimental

(2S)-2-AMINO-1-(5-TERT-BUTYL-1,3,4-OXADIAZOL-2-YL)PROPAN-1-ONE

Experimental

2-(TOLUENE-4-SULFONYL)-2H-BENZO[D][1,2,3]DIAZABORININ-1-OL

Experimental

Brequinar

Experimental

Apatorsen

Apatorsen is a second generation antisense drug which in preclinical experiments, inhibits production of Heat Shock Protein 27 (Hsp27) a cell survival protein found at elevated levels in many human cancers including prostate, lung, breast, ovarian, bladder, renal, pancreatic, multiple myeloma and liver cancer.
Investigational
Displaying drugs 6026 - 6050 of 6770 in total